» Articles » PMID: 17685742

A Meta-analytic Review of Double-blind, Placebo-controlled Trials of Antidepressant Efficacy of Omega-3 Fatty Acids

Overview
Specialty Psychiatry
Date 2007 Aug 10
PMID 17685742
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Evidence has indicated an association between depression and low dietary intake of omega-3 polyunsaturated fatty acids (PUFAs). However, clinical trials examining the therapeutic benefit of omega-3 PUFAs in depression showed inconsistent results. The goal of this study is to systematically evaluate the antidepressant efficacy of omega-3 PUFAs by using meta-analytic method.

Data Sources: MEDLINE, Embase, and PsycINFO databases were searched from 1966 through August 2006 using the key words (depression OR depressive disorder OR mood disorder) AND (omega-3 OR EPA OR DHA OR poly-unsaturated fatty acid OR fish oil). The search was limited to literature in English and clinical trials.

Study Selection: Ten double-blind, placebo-controlled studies in patients with mood disorders receiving omega-3 PUFAs with the treatment period lasting 4 weeks or longer were included.

Data Extraction: Effect size (ES) of each individual study was derived by computing the standardized mean difference. A random-effects model was used to pool the ESs of all included studies.

Data Synthesis: When pooling the results of 10 included studies (N = 329), we found a significant antidepressant effect of omega-3 PUFAs (ES = 0.61, p = .003). Likewise, omega-3 PUFAs significantly improved depression in patients with clearly defined depression (ES = 0.69, p = .002) or with bipolar disorder (ES = 0.69, p = .0009). The dosage of eicosapentaenoic acid (EPA) did not change the antidepressant efficacy significantly. However, significant heterogeneity among these studies and publication bias were noted.

Conclusions: Although our meta-analysis showed significant antidepressant efficacy of omega-3 PUFAs, it is still premature to validate this finding due to publication bias and heterogeneity. More large-scale, well-controlled trials are needed to find out the favorable target subjects, therapeutic dose of EPA, and the composition of omega-3 PUFAs in treating depression.

Citing Articles

The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Wu S, Yang K, Liu W, Malau I, Zailani H, Chang C Nutrients. 2024; 16(21).

PMID: 39519521 PMC: 11547719. DOI: 10.3390/nu16213688.


Omega-3 Polyunsaturated Fatty Acids and Blood-Brain Barrier Integrity in Major Depressive Disorder: Restoring Balance for Neuroinflammation and Neuroprotection.

Zailani H, Wang W, Satyanarayanan S, Chiu W, Liu W, Sung Y Yale J Biol Med. 2024; 97(3):349-363.

PMID: 39351324 PMC: 11426295. DOI: 10.59249/YZLQ4631.


1-Methyltryptophan treatment ameliorates high-fat diet-induced depression in mice through reversing changes in perineuronal nets.

Hu J, Zhang S, Wu H, Wang L, Zhang Y, Gao H Transl Psychiatry. 2024; 14(1):228.

PMID: 38816357 PMC: 11139877. DOI: 10.1038/s41398-024-02938-4.


Indulging Curiosity: Preliminary Evidence of an Anxiolytic-like Effect of Castor Oil and Ricinoleic Acid.

Nisbett K, Vendruscolo L, Koob G Nutrients. 2024; 16(10).

PMID: 38794765 PMC: 11124509. DOI: 10.3390/nu16101527.


The role of polyunsaturated fatty acids in the neurobiology of major depressive disorder and suicide risk.

Sublette M, Daray F, Gananca L, Shaikh S Mol Psychiatry. 2023; 29(2):269-286.

PMID: 37993501 DOI: 10.1038/s41380-023-02322-6.